Other Guidelines | Page 59 | European Cystic Fibrosis Society (ECFS)

The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis

Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis

Glucose ingestion in cystic fibrosis induces severe redox imbalance: a potential role in diabetes

Azithromycin and Tezacaftor/Ivacaftor is associated with first-degree heart block in an adult with Cystic Fibrosis

Pregnancy outcomes in women with cystic fibrosis and poor pulmonary function

Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Cystic Fibrosis Related Diabetes; Glucose challenge test; Oral glucose tolerance test.

first
previous
…
55
56
57
58
59
60
61
62
63
…
next
last